These secondary patents will expire later than Novo Nordisks foundational patent and have the potential to delay or complicate market entry by generic manufacturers
doi:10.1007/bf00191904
Manufactured by Novo Nordisk at a list price approaching $1,000 per month, Wegovy was also the drug that most patients associated with the GLP-1 weight loss revolution
Thats why some people explore alternatives based on cost and likelihood of approval
Mounjaro puede contribuir a un mayor riesgo de tumores de clulas C de la tiroides, pancreatitis aguda, enfermedad de la vescula biliar, hipoglucemia, lesin renal aguda, efectos secundarios gastrointestinales graves, reacciones de hipersensibilidad y empeoramiento de la retinopata diabtica si padece diabetes tipo 2
Lunch might be a salad or grain bowl built around grilled chicken, fish, or beans, with plenty of vegetables and a whole grain